WRN and neoplasm: GSK_WRN4 induced DNA damage specifically in MSI-H tumors, but not other tissues, demonstrating that the in vivo tumor growth inhibition by GSK_WRN4 at 300 mpk is due to WRN helicase inhibition rather than off-target toxicity.